RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 The ATLAS Trial: Long-Term Adalimumab Treatment Reduces Signs and Symptoms in Ankylosing Spondylitis Patients
JF MD Conference Express
YR 2006
FD SAGE Publications
VO 6
IS 3
SP 15
OP 16
DO 10.1177/155989770600600310
UL http://mdc.sagepub.com/content/6/3/15.2.abstract
AB The Adalimumab Trial Evaluating Long-Term Efficacy and Safety in Ankylosing Spondylitis (AS) or ATLAS trial was a double-blind, phase III, placebo-controlled study to evaluate the ability of adalimumab to reduce signs and symptoms of AS over a one-year period.